Selenomethionine ameliorates cognitive decline, reduces tau hyperphosphorylation, and reverses synaptic deficit in the triple transgenic mouse model of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 41, Issue 1, 2014, Pages 85-99

  Song, Guoli ^a   Zhang, Zhonghao ^a   Wen, Lei ^a   Chen, Chen ^a   Shi, Qingxue ^a   Zhang, Yu ^a   Ni, Jiazuan ^a   Liu, Qiong ^a  

^a SHENZHEN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; selenomethionine; tau; transgenic mouse model

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOPROTEIN PHOSPHATASE 2A; SELENOMETHIONINE; SYNAPTOPHYSIN; TAU PROTEIN; DLGH4 PROTEIN, MOUSE; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; GUANYLATE KINASE; MAPT PROTEIN, MOUSE; MEMBRANE PROTEIN; NEUROPROTECTIVE AGENT; PHOSPHOPROTEIN PHOSPHATASE 2; SELENIUM; SYP PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; HIPPOCAMPUS; MENTAL DETERIORATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYNAPSE; ANIMAL; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GLIA; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CEREBRAL CORTEX; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; GUANYLATE KINASE; HIPPOCAMPUS; MALE; MEMBRANE PROTEINS; MICE, TRANSGENIC; NEUROGLIA; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; SELENIUM; SELENOMETHIONINE; SYNAPSES; SYNAPTOPHYSIN; TAU PROTEINS;

EID: 84902215722     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131805     Document Type: Article

References (61)

1. Alzheimer's Association (2012) Alzheimer's disease: Facts and figures. Alzheimers Dement 8, 131-168.
2. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189.
3. Kerr ML, Small DH (2005) Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: Function, regulation of proteolysis, and implications for drug development. J Neurosci Res 80, 151-159.
4. Duan Y, Dong S, Gu F, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer's disease: Focusing on tau-mediated neurodegeneration. Transl Neurodegener 1, 24.
5. Venkateshappa C, Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK (2012) Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: Implications for neu-rodegeneration in Alzheimer's disease. Neurochem Res 37, 1601-1614.
6. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G (2004) Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis 17, 108-113.
7. Markesbery WR, Lovell MA (2007) Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64, 954-956.
8. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 59, 290-294.
9. Kryukov GV, Castellano SV, Novoselov S, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN (2003) Characterization of mammalian selenoproteomes. Science 300, 1439-1443.
10. Savarino L, Granchi D, Ciapetti G, Cenni E, Ravaglia G, Forti P, Maioli F, Mattioli R (2001) Serum concentrations of zinc and selenium in elderly people: Results in healthy nonagenarians/centenarians. Exp Gerontol 36, 327-339.
11. Akbaraly TN, Hininger-Favier I, Carrière I, Arnaud J, Gourlet V, Roussel AM, Berr C (2007) Plasma selenium over time and cognitive decline in the elderly. Epidemiology 18, 52-58.
12. Gao S, Jin Y, Hall KS, Liang C, Unverzagt FW, Ji R, Murrell JR, Cao J, Shen J, Ma F, Matesan J, Ying B, Cheng Y, Bian J, Li P, Hendrie HC (2007) Selenium level and cognitive function in rural elderly Chinese. Am J Epidemiol 165, 955-965.
13. Cardoso BR, Ong TP, Jacob-Filho W, Jaluul O, Freitas MI, Cozzolino SM (2010) Nutritional status of selenium in Alzheimer's disease patients. Br J Nutr 103, 803-806.
14. Gwon AR, Park JS, Park JH, Baik SH, Jeong HY, Hyun DH, Park KW, Jo DG (2010) Selenium attenuates A beta production and A beta-induced neuronal death. Neurosci Lett 469, 391-395.
15. Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, Ahmad A, Shrivastav P, Islam F (2009) Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 1281, 117-127.
16. Liu MC, Xu Y, Chen YM, Li J, Zhao F, Zheng G, Jing JF, Ke T, Chen JY, Luo WJ (2013) The effect of sodium selenite on lead induced cognitive dysfunction. Neurotoxicology 36, 82-88.
17. Van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neu-rodegeneration, and functional deficits inAlzheimer's disease models. Proc Natl Acad Sci USA 107, 13888-13893.
18. Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, Sundstrom LE, Costello AJ, Hovens CM (2010) Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci 17, 1025-1033.
19. Daniels LA (1996) Selenium metabolism and bioavailability. Biol Trace Elem Res 54, 185-199.
20. Xiong S, Markesbery WR, Shao C, Lovell MA (2007) Seleno-L-methionine protects against beta-amyloid and iron/hydrogen peroxide-mediated neuron death. Antioxid Redox Signal 9, 457-467.
21. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24, 1063-1070.
22. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Afj causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
23. Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63, 1155-1162.
24. Chauhan V, Chauhan A (2006) Oxidative stress in Alzheimer's disease. Pathophysiology 13, 195-208.
25. Schweizer U, Schomburg L, Savaskan NE (2004) The neurobiology of selenium: Lessons from transgenic mice. JNutr 134, 707-710.
26. Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, Passaro A, Fellin R (2004) Trace elements and cognitive impairment: An elderly cohort study. Arch Gerontol Geriatr Suppl 9, 393-402.
27. Gao S, Jin Y, Hall KS, Liang C, Unverzagt FW, Ma F, Cheng Y, Shen J, Cao J, Matesan J, Li P, Bian J, Hendrie HC, Murrell JR (2009) Selenium level is associated with apoE epsilon4 in rural elderly Chinese. Public Health Nutr 12, 2371-2376.
28. Cardoso BR, Cominetti C, Cozzolino SM (2013) Importance and management of micronutrient deficiencies in patients with Alzheimer's disease. Clin Interv Aging 8, 531-542.
29. Mendelev N, Mehta SL, Idris H, Kumari S, Li PA (2012) Selenite stimulates mitochondrial biogenesis signaling and enhances mitochondrial functional performance in murine hippocampal neuronal cells. PLoS One 7, e47910.
30. Lovell MA, Xiong S, Lyubartseva G, Markesbery WR (2009) Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radic Biol Med 46, 1527-1533.
31. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
32. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
33. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L (2010) Tau reduction prevents Afj-induced defects in axonal transport. Science 330, 198.
34. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA (2010) Neuroinflammation-an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 7, 38-41.
35. Thangavel R, Stolmeier D, Yang X, Anantharam P, Zaheer A (2012) Expression of glia maturation factor in neuropatho-logical lesions of Alzheimer's disease. Neuropathol Appl Neurobiol 38, 572-581.
36. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D (2010) Inflammation in Alzheimer's disease: Relevance to pathogenesis and therapy. Alzheimers Res Ther 22, 1.
37. Kashon ML, Ross GW, O'Callaghan JP, Miller DB, Petro-vitch H, Burchfiel CM, Sharp DS, Markesbery WR, Davis DG, Hardman J, Nelson J, White LR (2004) Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis 6, 595-604.
38. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Afj and synaptic dysfunction. Neuron 39, 409-421.
39. Heneka MT, Rodriguez JJ, Verkhratsky A (2010) Neuroglia in neurodegeneration. Brain Res Rev 63, 189-211.
40. Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19, 12-20.
41. Ishibashi K, Tomiyama T, Nishitsuji K, Hara M, Mori H (2006) Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain. J Neurosci Res 84, 632-636.
42. Sivanesan S, Tan A, Rajadas J (2013) Pathogenesis of Afj oligomers in synaptic failure. Curr Alzheimer Res 10, 316-323.
43. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56, 127-129.
44. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25, 11061-11070.
45. Dinamarca MC, Colombres M, Cerpa W, Bonansco C, Inestrosa NC (2008) Beta-amyloid oligomers affect the structure and function of the postsynaptic region: Role of the Wnt signaling pathway. Neurodegener Dis 5, 149-152.
46. Tamagno E, Bardini P, Guglielmotto M, Danni O, Tabaton M (2006) The various aggregation states of fj-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic Biol Med 41, 202-212.
47. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol 59, 972-976.
48. Mandal PK, Tripathi M, Sugunan S (2012) Brain oxidative stress: Detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 417, 43-48.
49. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384, 505-516.
50. Resende R, Moreira PI, Proença T, Deshpande A, Busciglio J, Pereira C, Oliveira CR (2008) Brain oxidative stressinatriple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44, 2051-2057.
51. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K (2011) Abeta (1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 14, 545-547.
52. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Win-blad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropath Exp Neurol 58, 1010-1019.
53. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83, 1529-1533.
54. Gómez-Sintes R, Hernández F, Bortolozzi A, Artigas F, Avila J, Zaratin P, Gotteland JP, Lucas JJ (2007) Neuronal apopto-sis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 26, 2743-2754.
55. Hurtado DE, Molina-Porcel L, Carroll JC, Macdonald C, Aboagye AK, Trojanowski JQ, Lee VM (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 32, 392-402.
56. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
57. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, Cao Y, Gustafsson JA, Winblad B, Pei JJ (2008) Phos-phorylated PP2A (tyrosine307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 12, 241-257.
58. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Phosphatase activity toward abnormally phosphory-lated tau: Decrease in Alzheimer disease brain. J Neurochem 65, 732-738.
59. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168, 402-412.
60. Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 15, 2321-2328.
61. Liu GP, Wei W, Zhou X, Shi HR, Liu XH, Chai GS, Yao XQ, Zhang JY, Peng CX, Hu J, Li XC, Wang Q, Wang JZ (2013) Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice. Mol Ther 189, 2247-2257.